ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

PCCA Appoints New Chief Financial Officer, Manfredo Thibau, MBA

Houston, Oct. 04, 2022 (GLOBE NEWSWIRE) -- PCCA announced today that Manfredo Thibau, MBA, formerly Vice President, Finance, of Vibrantz Technologies, Inc., has joined the company and started his preparation to assume the PCCA Chief Financial Officer (CFO) position on January 1, 2023. Current CFO Marc DuPont, who is set to retire in December after more than 20 years at PCCA, will remain in his position through the end of 2022 to help with the transition.

“We’re excited to have Manfredo join our PCCA family and continue our legacy of supporting compounding pharmacies and pharmacists,” said PCCA President Jim Smith. “Manfredo’s experience, education and financial acumen will be an asset to our strategic management team. Plus, his warm personality and service attitude align nicely with our PCCA culture and values.”

Thibau’s extensive financial background and work experience include serving as: Vice President, Financial Planning & Analysis, for Igloo Products Corp.: Director of Operations Finance for Pentair; and Manager, Business Development, for Eli Lilly and Company in Brazil. While at Eli Lilly and Company, he received Lilly’s 2012 Global CFO Award for leading and implementing a pricing program that provided free human insulin to all Brazilians.

Thibau earned his Master of Business Administration degree from UNC Kenaan-Flagler Business School, a graduate degree in finance from Harvard University and a Bachelor of Laws degree from Faculdades Milton Campos.

“I’m grateful to join PCCA, a pioneer in the compounding industry that truly cares about patients, pharmacists and independent pharmacies,” Thibau said. “For me, helping PCCA achieve its goals means I’m indirectly helping fill the unmet needs of patients. That’s something very close to my heart. I’m also especially grateful to have Marc DuPont here to guide me, answer questions, make introductions and help throughout the transition.”

“There’s no doubt, Manfredo will be embraced and welcomed by our PCCA family,” DuPont said. “We truly care about each other, our members and the compounding industry. The past 20 years with the company have been incredible. I’ve developed lasting friendships with coworkers and PCCA members. We’ve overcome challenges, laughed a lot and, at times, even cried together. I’m blessed to have been a part of PCCA’s legacy and look forward to watching PCCA continue to develop innovative products and services for our members and the compounding industry as a whole.”

 

ABOUT PCCA

PCCA supports the creation of personalized medicine and innovative products that make a difference in patients’ lives. As a complete resource for independent compounding pharmacies and health systems, PCCA provides high-quality products, education and support to more than 3,000 pharmacy members throughout the United States, Canada, Australia and other countries around the world. Incorporated in 1981 by a network of pharmacists, PCCA has supported pharmacy compounding for more than 40 years. Learn more at pccarx.com.

Attachment


Kim Speairs, APR, MBA
PCCA
817.729.5064
kspeairs@pccarx.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  221.84
-0.70 (-0.31%)
AAPL  273.12
-0.99 (-0.36%)
AMD  207.64
+0.06 (0.03%)
BAC  54.89
-0.44 (-0.80%)
GOOG  305.73
-3.59 (-1.16%)
META  653.42
+5.91 (0.91%)
MSFT  474.19
-0.63 (-0.13%)
NVDA  176.21
-0.08 (-0.05%)
ORCL  188.52
+3.60 (1.95%)
TSLA  478.10
+2.79 (0.59%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.